Work

Intraoperative administration of Hextend® versus 6% Hetastrach in saline for the treatment of hypovolemia during major surgery: preliminary results of a randomized clinical trial

Year: 1998

Type: conference-abstract

Abstract: Hextend ® is a new 6% hydroxyethyl starch (mean molecular weight 550 Kd) in a balanced and buffered electrolyte and glucose solution intended for use as a plasma expander. In animal models Hextend ® appears to offer significant advantages over currently available alternatives (e.g Hespan ® ) in terms of acid/base/electrolyte/glucose balance and survival. Hextend can potentially serve as an economical, sterile, physiologically-balanced replacement for blood volume lost subsequent to trauma related bleeding. It may also be used to induce mild to moderate hypothermia in order to prolong survival time during transport to a critical care center. We report here the preliminary results of the on-going phase III study of Hextend ® .

Source: Critical Care

DOI: 10.1186/cc204